101
Participants
Start Date
May 31, 2012
Primary Completion Date
June 30, 2015
Study Completion Date
June 30, 2015
Placebo
Placebo for 0.8 g sachets of powder for oral suspension or 800 mg tablets
Sevelamer carbonate
0.8 g sachets of powder for oral suspension or 800 mg tablets
Investigational Site Number 8201, Berlin
Investigational Site Number 8018, Buffalo
Investigational Site Number 8011, Philadelphia
Investigational Site Number 8012, Baltimore
Investigational Site Number 8002, Charlottesville
Investigational Site Number 8009, Greenville
Investigational Site Number 8007, Atlanta
Investigational Site Number 8025, Orlando
Investigational Site Number 8101, Bordeaux
Investigational Site Number 8202, Marburg
Investigational Site Number 8003, Birmingham
Investigational Site Number 8005, Birmingham
Investigational Site Number 8020, Detroit
Investigational Site Number 8302, Kaunas
Investigational Site Number 8023, St Louis
Investigational Site Number 8022, Kansas City
Investigational Site Number 8102, Bron
Investigational Site Number 8026, Dallas
Investigational Site Number 8103, Paris
Investigational Site Number 8016, Houston
Investigational Site Number 8001, San Antonio
Investigational Site Number 8013, Los Angeles
Investigational Site Number 8014, San Francisco
Investigational Site Number 8006, Seattle
Investigational Site Number 8019, Iowa City
Investigational Site Number 8402, Gdansk
Investigational Site Number 8008, Boston
Investigational Site Number 8017, Livingston
Investigational Site Number 8010, Portland
Investigational Site Number 8027, Richmond
Investigational Site Number 8301, Vilnius
Investigational Site Number 8401, Krakow
Genzyme, a Sanofi Company
INDUSTRY